
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
The FDA's Oncology Drug Advisory Committee has not recommended approval of atrasentan (Xinlay), an oral agent for the treatment of metastatic hormone-refractory prostate cancer.
The FDA's Oncology Drug Advisory Committee has not recommended approval of atrasentan (Xinlay), an oral agent for the treatment of metastatic hormone-refractory prostate cancer. The drug is a once-daily, non-hormonal, non-chemotherapy selective endothelin-A receptor antagonist, which is currently being studied in an ongoing phase III trial in hormone-refractory prostate cancer patients without metastasis. The study is expected to be completed in 2006.





